Specialised Therapeutics Australia

18 PBAC submissions on file, active 2008–2025. 72% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Ponatinib
  Haematology · Recommended with restriction · 2018—
• Netupitant/palonosetron
  Oncology · Recommended with restriction · 2015—
• Paclitaxel, nanoparticle albumin-bound
  Oncology · Recommended with restriction · 2019—
• Palopegteriparatide
  Endocrinology · Recommended with restriction · 2025—
• Plitidepsin
  Haematology · Not recommended · 2020—
• Lurbinectedin
  Oncology · Recommended with restriction · 2025—
• Nab-paclitaxel
  Oncology · Not recommended · 2015—
• Netupitant and palonosetron
  Oncology · Recommended with restriction · 2015—
• Paclitaxel-nanoparticle albumin bound
  Oncology · Recommended with restriction · 2014—
• Palonosetron hydrochloride
  Oncology · Recommended with restriction · 2010—
• Trabectedin
  Oncology · Recommended with restriction · 2021—

Therapy area mix

Activity by year

2008 (1) · 2010 (1) · 2014 (2) · 2015 (5) · 2017 (1) · 2018 (1) · 2019 (2) · 2020 (1) · 2021 (1) · 2025 (3)

Rejection patterns

Across 4 Not recommended decisions on file.

• 1×unclear clinical place particularly for moderately emetogenic chemotherapy population
• 1×lack of clinical evidence for patients with prior chemotherapy-induced nausea/vomiting
• 1×concerns about potential leakage into populations where combination therapy may not be required
• 1×insufficient robustness of clinical evidence to support cost-minimisation analysis
• 1×pricing of fixed dose combination difficult to establish without individual PBS-listed components